Pavicevic Sandra, Reichelt Sophie, Uluk Deniz, Lurje Isabella, Engelmann Cornelius, Modest Dominik P, Pelzer Uwe, Krenzien Felix, Raschzok Nathanael, Benzing Christian, Sauer Igor M, Stintzing Sebastian, Tacke Frank, Schöning Wenzel, Schmelzle Moritz, Pratschke Johann, Lurje Georg
Department of Surgery, Campus Charité Mitte, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Department of Gastroenterology and Hepatology, Campus Charité Mitte, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Cancers (Basel). 2022 Feb 17;14(4):1026. doi: 10.3390/cancers14041026.
Cholangiocarcinoma (CCA) is the second most common primary liver cancer and subsumes a heterogeneous group of malignant tumors arising from the intra- or extrahepatic biliary tract epithelium. A rising mortality from CCA has been reported worldwide during the last decade, despite significant improvement of surgical and palliative treatment. Over 50% of CCAs originate from proximal extrahepatic bile ducts and constitute the most common CCA entity in the Western world. Clinicopathological characteristics such as lymph node status and poor differentiation remain the best-studied, but imperfect prognostic factors. The identification of prognostic molecular markers as an adjunct to traditional staging systems may not only facilitate the selection of patients who would benefit the most from surgical, adjuvant or palliative treatment strategies, but may also be helpful in defining the aggressiveness of the disease and identifying patients at high-risk for tumor recurrence. The purpose of this review is to provide an overview of currently known molecular prognostic and predictive markers and their role in CCA.
胆管癌(CCA)是第二常见的原发性肝癌,包括一组起源于肝内或肝外胆管上皮的异质性恶性肿瘤。尽管手术和姑息治疗有了显著改善,但在过去十年中,全球范围内CCA导致的死亡率仍在上升。超过50%的CCA起源于肝外近端胆管,是西方世界最常见的CCA类型。诸如淋巴结状态和低分化等临床病理特征仍是研究最多但并不完善的预后因素。识别预后分子标志物作为传统分期系统的辅助手段,不仅可以促进选择能从手术、辅助或姑息治疗策略中获益最大的患者,还可能有助于界定疾病的侵袭性并识别肿瘤复发高危患者。本综述的目的是概述目前已知的分子预后和预测标志物及其在CCA中的作用。